The global regenerative medicines market is
already an established market. However, emerging submarkets such as cell and
gene therapy and stem cell therapy continue to be in a preliminary stage now,
anticipating tremendous growth in the short-term. With an increasing number of
companies attempting to enter the market with pipelines having high potential,
this market will witness tremendous dynamicity. In addition, the growing
consolidation in the market is expected to attract more emerging companies to
enter the market.
The global market for regenerative medicines generated $21.59 billion in 2019 and is projected to reach the value of $87.03 billion by 2030 with a CAGR of 13.99% during 2020-2030.
Market Segmentation
• Product – Tissue Engineering (Allogeneic Tissue, Autologous Tissue, Xenogeneic Tissue, and Synthetic Tissue), Stem Cells (Stem Cell Services and Stem Cell Therapies), and Cell ang Gene Therapy (Car-T Cell Therapy, Gene Therapy, Other Cell Therapies)
• Application – Orthopedic and Musculoskeletal, Oncology, Wound Care, Cardiology, Immunology, Dermatology, and Other Applications
Regional Segmentation
• North America – U.S., and Canada
• Europe – Germany, U.K., France, Italy, Spain, Netherlands, Russia, and Rest-of-Europe
• Asia-Pacific – China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific
• Latin America – Brazil, Mexico, and Rest-of-Latin America
• Rest-of-the-World
Growth Drivers
• Increasing Consolidation Among Healthcare Juggernauts
• Rising Number of Clinical Trials for Regenerative Therapies
• A Favorable Regulatory Environment to Accelerate Approvals and Market Entry
• A Rising Awareness for Stem Cell Therapeutics
Market Restraints
• Lack of Reliable Vector Production for Cell and Gene Therapy
• Exorbitant Cost of Next-Generation Therapies
Market Opportunities
• Drug Approvals and Strong Pipeline of Cell and Gene Therapies
• Multiple Investments in Expansion of cGMP Units
• Innovations in Regenerative Medicine
Key Companies Profiled
AbbVie, Inc., Baxter International Inc., Becton, Dickinson and Company, Dendreon Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., Integra LifeSciences Holdings Corporation, Johnson & Johnson, Medtronic plc, Mesoblast Ltd., Novartis International A.G., NuVasive, Inc., Organogenesis Holdings, Inc., Smith & Nephew plc, Stryker Corporation, Vericel Corporation, and Zimmer Biomet Holdings, Inc.
Request a Sample - https://bisresearch.com/requestsample?id=1092&type=download
Comments
Post a Comment